Oncoinvent issues shares to settle underwriting fees

Oncoinvent ASA announced it would increase its share capital, issuing 31,199,997 new shares to settle underwriting fees related to its fully underwritten rights issue. This move, authorized by an extraordinary general meeting on August 4, 2025, addresses the underwriting commission for the NOK 130 million rights issue, which comprised 260,000,000 new shares.

The newly issued "Underwriting Commission Shares" have a subscription price of NOK 0.50 each, matching the subscription price of the rights issue shares. This transaction increases the company's share capital by NOK 15,599,998.50. The share capital increase is expected to be registered by December 9, 2025, with shares delivered to underwriters around December 10, 2025.

Oncoinvent is a clinical-stage biotechnology company listed on the Oslo Stock Exchange, specializing in radiopharmaceutical therapies for cancer. Its lead candidate, Radspherin®, an alpha-emitting radionuclide therapy, is currently undergoing a randomized Phase 2 trial in ovarian cancer.